Principles of pregnancy management in women with Ph-negative myeloproliferative neoplasms


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To comparatively analyze the course of 167 pregnancies in 95 women with Ph-negative myeloproliferative neoplasms (MPN) who have been treated and untreated for the underlying disease. Material and methods. Complications of pregnancy, delivery, and postpartum period and neonatal health status were evaluated in both groups. Results. The creation of a program for pregnancy preparation and management in women with Ph-negative MPN led to a significant reduction in reproductive losses from 76.3% to 3.3% and to a downward trend in the number of pregnancy complications from 84,6% to 74.2%. The health status and frequency of malformations in children born to the mothers with MPN who had been treated during pregnancy did not differ from those in the healthy population. Conclusion. Pregnant women with Ph-negative MPN belong to a high-risk group. The results of the investigation have shown that pregnancy has no impact on the course of myeloproliferative disease. The algorithm elaborated by the authors could substantially reduce reproductive losses and the number of pregnancy complications in women with MPN. The health status of the children does not differ from that in the general population.

Full Text

Restricted Access

About the authors

Roman Georgievich Shmakov

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: r_shmakov@oparina4.ru
MD, chief medical officer

Evgenia Sergeevna Polushkina

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_polushkina@oparina4.ru
Ph.D, senior

Aminat Isaevna Akhmedova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_ahmedova@oparina4.ru
postgraduate student

Manana Alexsandrovna Sokolova

Hematology Research Center, Ministry of Health of Russia

Email: s_manana@mail.ru
Ph.D, senior

Maria Alekseevna Vinogradova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: m_vinogradova@oparina4.ru
Ph.D, head of the department of transfusiology and extracorporeal detoxication

References

  1. Alimam S., Bewley S., Chappell L.C., Knight M., Seed P., Gray G. et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br. J. Haematol. 2016; 175(1): 31-6.
  2. Lavi N., Horowitz N.A., Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond.). 2014; 10(3): 255-66.
  3. Skeith L., Carrier M., Robinson S.E., Alimam S., Rodger M.A. Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood. 2017; 129(8): 934-9.
  4. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26): 5128-33.
  5. Rumi E., Bertozzi I., Casetti I.C., Roncoroni E., Cavalloni C., Bellini M. et al.; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015; 100(11): e443-5.
  6. El-Hemaidi I., Robinson S.E. Management of haematological malignancy in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2012; 26(1): 149-60.
  7. Health and Social Care Information Centre (HSCIC). NHS Maternity Statistics -England, 2010-2011.
  8. Aviles A., Neri N., Nambo M.J. Hematological malignancies and pregnancy: treat or not treat during first trimester. Int. J. Cancer. 2012; 131(11): 2678-83.
  9. Lavi N., Brenner B., Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb. Res. 2013; 131(Suppl. 1): S11-3.
  10. Umazume T., Yamada T., Akaishi R., Araki N., Nishida R., Morikawa M., Minakami H. Essential thrombocythemia as a risk factor for stillbirth. Thromb. Res. 2014; 133(2): 158-61.
  11. Gerds A.T., Dao K.H. Polycythemia vera management and challenges in the community health setting. Oncology. 2017; 92(4): 179-89.
  12. Horowitz N.A., Lavi N., Nadir Y., Brenner B. Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks. Thromb. Haemost. 2016; 16(4): 613-7.
  13. Pieri L., Guglielmelli P., Vannucchi A.M. Chronic myeloproliferative neoplasms: a collaborative approach. Mediterr. J. Hematol. Infect. Dis. 2010; 2(2): e2010017.
  14. Gangat N., Wolanskyj A.P., Schwager S., Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur. J. Haematol. 2009; 82(5): 350-3.
  15. Сухих Г.Т., Давыдов М.И., Савченко В.Г. Репродуктивное здоровье женщин с онкогематологическими заболеваниями. М.; 2012: 172-8. [Sukhikh G.T., Davydov M.I., Savchenko V.G. Reproductive health of women with oncohematological diseases. Moscow; 2012: 172-8. (in Russian)]
  16. Amit O., Barzilai M., Avivi I. Management of hematologic malignancies: special considerations in pregnant women. Drugs. 2015; 75(15): 1725-38.
  17. Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M. et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukaemiaNet. J. Clin. Oncol. 2011; 29(6): 761-70.
  18. Yazdani Brojeni P., Matok I., Garcia Bournissen F., Koren G. A systematic review of the fetal safety of interferon alpha. Reprod. Toxicol. 2012; 33(3): 265-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media